Andrew Weiskopf

home / authors / andrew-weiskopf

Andrew Weiskopf is director, technical development, Biogen Idec

Articles

Defining Critical Quality Attributes for Monoclonal Antibody Therapeutic Products

Defining Critical Quality Attributes for Monoclonal Antibody Therapeutic Products

Andrew J. Reason;Andrew Weiskopf;Anurag S. Rathore

Establishing the CQAs of a mAb product by evaluating impact and uncertainty during risk assessment.

Latest Updated Articles

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 11th 2024 | Updated: September 18th 2024

CPHI Pharma Award Finalists Announced for 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Published: March 27th 2024 | Updated: June 28th 2024

AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product

Published: December 9th 2024 | Updated: December 22nd 2024

Recap Key Industry Trends for Viral Clearance and NGS

Shining Pro - Stock.Adobe.com

Published: December 7th 2024 | Updated: December 22nd 2024

Enhancing Quality Through Training

Published: July 20th 2020 | Updated: December 22nd 2024

Contact BioPharm International Editors

Published: July 19th 2020 | Updated: December 22nd 2024

Editorial Information: BioPharm International Submission Guidelines and Editorial Calendars

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.